BRCA1 and breast cancer: Consistent estimates were also found for the association between COX-2 inhibitors and BC risk for women not known to be mutation carriers (HRc = 0.34, 95% CI = 0.25 to 0.48), BRCA1 carriers (HRc = 0.46, 95% CI = 0.20 to 1.08), and BRCA2 carriers (HRc = 0.51, 95% CI = 0.26 to 1.03); confidence intervals were again wide for known mutation carriers.